Is hypofractionation acceptable for prostate bed radiotherapy?

Urol Oncol. 2021 Feb 23:S1078-1439(21)00060-0. doi: 10.1016/j.urolonc.2021.02.002. Online ahead of print.ABSTRACTApproximately 30% of patients who undergo radical prostatectomy for prostate cancer develop disease progression. The only potentially curative treatment in these patients is postoperative radiotherapy with or without hormonotherapy. One of the standards of care in nonsurgical patients is hypofractionated radiotherapy. However, the current evidence based is insufficient to define the optimal dose and fractionation schedule for postoperative radiotherapy. In this context, the aim of this editorial is to assess the main efficacy and toxicity data for postoperative hypofractionated radiotherapy and discuss the potential to implement this fractionation in routine clinical practice.PMID:34049781 | DOI:10.1016/j.urolonc.2021.02.002

Source: Urologic Oncology - May 29, 2021 Category: Urology & Nephrology Authors: Fernando L ópez Campos Gemma Sancho Pardo Xavier Maldonado Pijoan Thomas Zilli Felipe Cou ñago Lorenzo Asunci ón Hervás Morón Source Type: research